CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec by Carolyn Helms | Jun 18, 2024 | Portfolio News
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies by Carolyn Helms | Jun 17, 2024 | Portfolio News
Somatus Achieves 4-Star Rating for Health Plan Partner Kidney Population Through Whole-Person Clinical Quality Program by Carolyn Helms | Jun 12, 2024 | Portfolio News
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease by Carolyn Helms | Jun 11, 2024 | Portfolio News
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC by Carolyn Helms | Jun 6, 2024 | Portfolio News
